

*DB=PGPB,USPT; PLUR=YES; OP=AND*

<u>L10</u>	18	192	<u>L10</u>
------------	----	-----	------------

*DB=EPAB,JPAB,DWPI; PLUR=YES; OP=AND*

<u>L9</u>	L8	8	<u>L9</u>
-----------	----	---	-----------

*DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND*

<u>L8</u>	L7 and hepatitis adj C	200	<u>L8</u>
-----------	------------------------	-----	-----------

<u>L7</u>	artem\$	10253	<u>L7</u>
-----------	---------	-------	-----------

*DB=PGPB,USPT; PLUR=YES; OP=AND*

<u>L6</u>	artem\$	3892	<u>L6</u>
-----------	---------	------	-----------

<u>L5</u>	L1 and flavivir\$	3	<u>L5</u>
-----------	-------------------	---	-----------

<u>L4</u>	L2 and flavivir\$	1	<u>L4</u>
-----------	-------------------	---	-----------

<u>L3</u>	L2 and hepatitis	2	<u>L3</u>
-----------	------------------	---	-----------

<u>L2</u>	L1 and artem\$	47	<u>L2</u>
-----------	----------------	----	-----------

<u>L1</u>	514/450.ccls.	917	<u>L1</u>
-----------	---------------	-----	-----------

END OF SEARCH HISTORY

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:573663 CAPLUS

DOCUMENT NUMBER: 119:173663

TITLE: Experimental study of inhibitory effect of the four traditional Chinese herb medicines on epidemic hemorrhagic fever virus

AUTHOR(S): Zheng, Xuanhe; Tang, Xiaopeng; Su, Xianshi

CORPORATE SOURCE: 2nd Affil. Hosp., Hunan Med. Univ., Changsha, Peop. Rep. China

SOURCE: Hunan Yike Daxue Xuebao (1993), 18(2), 165-7

CODEN: HYXBET; ISSN: 1000-5625

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

AB A laboratory observation of inhibitory effect of artemether, glycyrrhizin, houttuynia and bupleura on epidemic hemorrhagic fever virus (EHFV) infection is reported. The infection rates of the suckling mice treated with artemether and glycyrrhizin were much lower than that in the control group. The distribution of EHFV in the suckling mice on houttuynia and bupleura was different from that in the control group. It is indicated that artemether and glycyrrhizin can markedly prevent the EHFV infection in suckling mice. Moreover, houttuynia and bupleura might inhibit EHFV infection to some extent.

p

## Freeform Search

---

<b>Database:</b>	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database <b>EPO Abstracts Database</b> <b>JPO Abstracts Database</b> <b>Derwent World Patents Index</b> IBM Technical Disclosure Bulletins
<b>Term:</b>	L19 not Capillary adj artemisia <span style="float: right;">▲▼</span>
<b>Display:</b>	<input type="text" value="10"/> Documents in <b>Display Format:</b> <input type="text" value="-"/> Starting with Number <input type="text" value="1"/>
<b>Generate:</b> <input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image	

---

Search

Clear

Interrupt

---

### Search History

---

**DATE:** Monday, June 04, 2007   
 [Purge Queries](#)   
 [Printable Copy](#)   
 [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=EPAB,JPAB,DWPI; PLUR=YES; OP=AND</i>			
<u>L22</u>	L19 not Capillary adj artemisia	40	<u>L22</u>
<u>L21</u>	L20 and artemisinin	6	<u>L21</u>
<u>L20</u>	L19	96	<u>L20</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND</i>			
<u>L19</u>	l7 and hepatitis	566	<u>L19</u>
<i>DB=USPT; PLUR=YES; OP=AND</i>			
<u>L18</u>	l7 and hepatitis	118	<u>L18</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND</i>			
<u>L17</u>	5246930	4	<u>L17</u>
<u>L16</u>	L14 and (virus or antivir\$)	28	<u>L16</u>
<u>L15</u>	L14 and hepatitis	6	<u>L15</u>
<u>L14</u>	qinghao or qinghaosu	128	<u>L14</u>
<u>L13</u>	artemisia adj anuual	0	<u>L13</u>
<u>L12</u>	(artemisia or A) adj anuual	0	<u>L12</u>
<i>DB=USPT; PLUR=YES; OP=AND</i>			
<u>L11</u>	L10	25	<u>L11</u>

=> d hist

(FILE 'HOME' ENTERED AT 10:40:35 ON 04 JUN 2007)

FILE 'REGISTRY' ENTERED AT 10:41:31 ON 04 JUN 2007

L1 99 S ARTEMISININ  
L2 1 S ARTEMETHER/CN  
L3 1 S ARTEETHER/CN  
L4 1 S ARTESUNATE/CN

FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:43:54 ON 04 JUN 2007

L5 7624 S ARTEMISININ  
L6 67 S L5 AND HEPATITIS  
L7 53 DUPLICATE REM L6 (14 DUPLICATES REMOVED)  
L8 10 S L7 AND HEPATITIS (W) C  
L9 21 S L7 AND PY<=2003  
L10 5 S L9 AND (VIRUS OR ANTIVIRAL)

FILE 'STNGUIDE' ENTERED AT 10:50:53 ON 04 JUN 2007

FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:52:09 ON 04 JUN 2007

L11 8913 S L1 OR L2 OR L3 OR L4  
L12 80 S L11 AND HEPATITIS  
L13 29 S L12 AND PY<=2003  
L14 28 DUPLICATE REM L13 (1 DUPLICATE REMOVED)  
L15 24 S L14 NOT L10


FILE 'STNGUIDE' ENTERED AT 10:58:44 ON 04 JUN 2007

FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE' ENTERED AT 11:00:04 ON 04 JUN 2007

L16 9 S L11 AND FLAVIVIRID?  
L17 6 DUPLICATE REM L16 (3 DUPLICATES REMOVED)  
L18 6 S L17 NOT L10  
L19 3 S L17 NOT L8

L23 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1999:234337 CAPLUS <<LOGINID::20070604>>  
 DOCUMENT NUMBER: 130:267461  
 TITLE: Preparation of artemisin derivative containing phenyl  
 and heterocyclic radicals  
 INVENTOR(S): Li, Yang; Yang, Yonghua; Liang, Jie; Shan, Feng; Wu,  
 Guangshao  
 PATENT ASSIGNEE(S): Shanghai Inst. of Materia Medica, Chinese Academy of  
 Sciences, Peop. Rep. China  
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 17 pp.  
 CODEN: CNXXEV  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
CN 1122806	A	19960522	CN 1994-113982	19941109 <--
CN 1049435	B	20000216		
PRIORITY APPLN. INFO.:			CN 1994-113982	19941109
OTHER SOURCE(S):		CASREACT 130:267461; MARPAT 130:267461		
GI				



AB Title artemisin derivs. [I; X = O, NH; R = Ph, R3 substituted Ph, 2 same or different R3 and R4 substituted Ph, the heterocyclic radical is alkali adenylyl, thymine, cytidine, uracil, and their R3 substituted groups, triazo-, and CONH2 or R3 substituted triazo-; R3 = R4 = hydroxy, alkoxy (C1-C4), alkyl (C1-C4), COOCH3, COOC2H5, NHCOCH3, nitro, halogen (F, Cl, Br, I), dihydrogen artemisin radical] are prepared by reaction of dihydrogen artemisin, dihydrogen artemisin acetate, dihydrogen artemisin trifluoroacetate, and anilines with R3 substituted groups, R3 or R3 and R4 substituted phenols, Ph compound, heterocyclic compound or its silicone ether derivs. in the presence of acidic catalyst, boron trifluoride etherate, SnCl4, TiCl4, trifluoroacetic acid, p-Me benzenesulfonic acid, trimethylsilyl triflate, H2SO4 and H3PO4 and polar solvent, alkyl halide, Et ether, acetonitrile, THF, pyridine, triethylamine, and methyl-sulfoxide at -10° to 40°. Phenylamino artemisin, 3-chloro-phenylamino artemisin, 4-artemisin, 3-nitro-phenoxy artemisin, 4-methoxy-phenoxy artemisin, 4-(methoxycarbonyl)-phenoxy artemisin, 4-acetamino-phenoxy artemisin, tris(artemisin) phloroglucin, 5-hydroxy-1,3-bis(artemisin) benzenediol, adenylyl artemisin, 5-fluoro-uracil artemisin, 3-aminocarbonyl triazo artemisin, and 2,4-dimethoxyphenyl artemisin were prepared as antitumor, antiviral, and antiparasitic agents.